Updated: October 27, 2026
The 2002 meeting abstract Effects of Hyperbaric Oxygen on Blood Glucose Levels by JA Niezgoda, W Kingston and SV Fabus raises a practical question: how does blood glucose behave around hyperbaric oxygen exposure? The bibliographic record identifies the topic, but it does not provide the abstract’s methods or results. It would therefore be misleading to claim that the authors found glucose rose, fell or stayed constant. What can be explained is why glucose monitoring matters, what affects its interpretation, and how clinical protocols address the issue.
Why examine blood glucose during hyperbaric oxygen exposure?
Hyperbaric oxygen therapy (HBOT) is delivered in a chamber at pressure above the surface atmosphere, with the patient breathing oxygen. A common treatment pressure is about 2.0–2.8 atmospheres absolute (ATA), although pressure and duration depend on the indication and prescription. At 2.0 ATA, the ambient pressure is twice surface pressure; this changes oxygen availability but does not, by itself, determine a patient’s blood-glucose response.
Glucose is measured in milligrams per decilitre (mg/dL) or millimoles per litre (mmol/L); 18 mg/dL is approximately 1 mmol/L. It is influenced by food, insulin and other medicines, illness, stress and activity. A glucose reading taken before chamber entry answers a different question from one taken during or after a session, so a useful study or clinical protocol specifies both timing and measurement method.
People with diabetes may be at risk of hypoglycaemia during or after treatment, particularly when meals, insulin or glucose-lowering medicines are not coordinated with the appointment. This is a reason for individual monitoring—not evidence that HBOT invariably lowers glucose. The treatment team should follow its own threshold and response plan rather than rely on a universal cutoff.
What do pressure and oxygen change in the body?
At the surface, oxygen is carried mainly by haemoglobin. Under pressure, more oxygen also dissolves in plasma; the size of that increase depends on the inspired oxygen fraction and the pressure. HBOT protocols commonly use near-100% oxygen, but chamber design, treatment pressure and air breaks vary. Oxygen exposure is prescribed and monitored because elevated oxygen pressure has potential adverse effects, including central nervous system oxygen toxicity and pulmonary effects with sufficient exposure.
Those oxygen-delivery changes do not translate into a simple glucose rule. Glucose concentration reflects the balance between glucose entering the blood and its uptake or storage, under hormonal control that includes insulin, glucagon and stress hormones. Hypoxia, illness and physical exertion can affect metabolism, but a clinical oxygen treatment is not equivalent to a predictable glucose-lowering intervention.
Accordingly, distinguish a measured change from its cause. A reading that differs from baseline may reflect the patient’s meal, medication timing, illness or measurement conditions as well as the chamber exposure. The 2002 record alone does not establish the direction, magnitude or clinical importance of any effect.
Why does this subject matter in diving medicine?
HBOT and scuba diving both involve pressure, but their exposures are not interchangeable. A chamber treatment is prescribed at a controlled pressure, often with oxygen breathing periods and a defined clinical indication. A scuba diver descends and ascends through changing ambient pressure while breathing a gas selected for the dive; oxygen partial pressure changes with depth and gas mix. For example, a gas containing 32% oxygen reaches an oxygen partial pressure of about 1.4 ATA at 33 metres of seawater, before accounting for local convention and depth calculation.
That distinction matters for people with diabetes. The 2023 consensus guidance from the Undersea and Hyperbaric Medical Society (UHMS) and the Divers Alert Network (DAN) addresses fitness-to-dive assessment, treatment plans and the risk of hypoglycaemia underwater. A diver may be unable to respond to symptoms safely at depth, so dive planning and personal monitoring are essential; a chamber glucose protocol should not be copied as a scuba plan.
For either setting, an individual decision should involve the clinician responsible for the condition and, where relevant, a physician experienced in diving medicine or hyperbaric medicine. A diagnosis alone does not answer whether a specific person can safely dive or receive a planned treatment.
What does research of this kind need to consider?
A robust study would report the treatment pressure in ATA, oxygen concentration, exposure duration and timing of air breaks, as well as glucose sampling times. It should identify whether glucose was measured with a laboratory assay, a finger-stick meter or continuous glucose monitoring (CGM). These methods do not measure in identical ways: CGM estimates interstitial glucose and can lag behind blood glucose when levels are changing rapidly.
Investigators should also record diabetes status, insulin and other glucose-lowering medicines, the time and content of the last meal, activity and acute illness. Repeated measurements before and after exposure help show whether an apparent difference is temporary, but they do not by themselves prove that oxygen caused it. A comparison group or a carefully defined baseline strengthens interpretation.
- Exposure: state pressure in ATA, inspired oxygen, session duration and sample times.
- Measurement: name the device or laboratory method, units, and whether readings are capillary, venous or interstitial.
- Context: report meals, medicines, diabetes status and symptoms that could change glucose.
- Clinical meaning: separate a statistically detectable difference from a change that requires treatment or alters care.
For patients, follow the treating centre’s written instructions about meals, medication and pre-treatment checks. Do not change insulin or postpone food on the basis of a general article; contact the hyperbaric team for a plan tailored to the prescribed session and personal treatment regimen.
How does the topic fit into hyperbaric research?
Hyperbaric research measures both treatment outcomes and responses elsewhere in the body. Blood glucose is a useful variable because it is routinely measurable and clinically relevant, especially for patients using insulin or medicines that can cause hypoglycaemia. Yet a result is useful only when the exposure, sampling method and patient context are described well enough to interpret it.
The Niezgoda, Kingston and Fabus item is a 2002 meeting abstract, not a full paper in the repository record described here. The available bibliographic details identify the question but do not establish its sample size, protocol or findings. Readers should treat claims about the study’s results as unverified unless they consult the original meeting record or a complete report. This limitation is important: a citation to a topic is not evidence for a particular clinical effect.
- 2.0–2.8 ATA commonly encountered HBOT treatment-pressure range; actual prescriptions vary by indication.
- 18 mg/dL equivalent to approximately 1 mmol/L of glucose.
- 2002 publication year listed for the Niezgoda, Kingston and Fabus meeting abstract.
Frequently asked questions
What is hyperbaric oxygen?
Why measure blood glucose in a hyperbaric setting?
Does hyperbaric oxygen therapy have the same conditions as scuba diving?
Citation details
- Title: Effects of Hyperbaric Oxygen on Blood Glucose Levels
- Authors: JA Niezgoda, W Kingston and SV Fabus
- Year: 2002
- Record type: Meeting abstract
- Repository record: Rubicon Research Repository, handle 123456789/1082
This article summarizes the bibliographic record and general clinical context; it does not reproduce the original abstract or report study data. The record available for this summary is insufficient to verify the abstract’s methods and findings. Consult the original publication record for those details and seek individualized advice from the treating clinician.
Related reading on Rubicon
| Feature | Hyperbaric oxygen treatment | Scuba diving |
|---|---|---|
| Setting | Pressurized clinical chamber | Underwater exposure with changing depth |
| Oxygen exposure | Usually prescribed oxygen breathing; pressure and schedule set by the treatment protocol | Depends on breathing-gas oxygen fraction and depth; partial pressure rises with depth |
| Glucose concern | Coordinate meal, medication and monitoring with the hyperbaric team | Plan for hypoglycaemia risk and the ability to respond safely underwater |
| Decision-maker | Treating hyperbaric clinician and diabetes-care team | Diving-medicine physician and diver’s clinical team |
Further topics in the Rubicon collection include diving pressure and gas laws, cold-water effects on diver metabolism, oxygen toxicity, hyperbaric oxygen treatment and Lyme disease, and blood glucose management in diving. These subjects provide context, but none replaces the original 2002 abstract or an individualized medical assessment.